Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Kadmon Pharmaceuticals & Nano Terra Announce Worldwide Exclusive Licensing Agreement: Novel ROCK2 Inhibitor Data Suggests Potential Activity in Unmet Medical Needs in Cancer, Autoimmune Diseases

Abstract:
Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra's drug discovery platform, Pharmacomer™ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences ("NT Life"), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.

Kadmon Pharmaceuticals & Nano Terra Announce Worldwide Exclusive Licensing Agreement: Novel ROCK2 Inhibitor Data Suggests Potential Activity in Unmet Medical Needs in Cancer, Autoimmune Diseases

New York, NY and Brighton, MA | Posted on April 25th, 2011

The product candidates and Pharmacomer™ Technology platform were developed by Surface Logix, Inc., a company founded by world-renowned Harvard chemist Professor George M. Whitesides, Ph.D., and recently acquired by Nano Terra. The founding technologies focus on breakthroughs in the functionality of pharmaceuticals at the molecular level which enable the discovery of new, small molecule drugs optimized to meet the challenges of human physiology and to evade the early development challenges of traditional medicinal chemistry practices.

The product candidates, SLx-2119, SLx-4090 and SLx-2101, are currently in early- to mid-stage clinical development for a variety of diseases. They target several novel pathways of disease by inhibiting the activity of specific enzymes such as ROCK2 (Rho-associated coiled-coiled kinase 2), the target of SLx-2119; MTP (enterocytic microsomal triglyceride transfer protein), the target of SLx-4090; and PDE5 (phosphodiesterase 5), the target of SLx-2101. SLx-2119, a selective ROCK2 inhibitor, is particularly noteworthy in that preclinical studies of ROCK2 function in vivo suggest that the drug may have therapeutic applications in a diverse spectrum of diseases, including metabolic syndrome, diabetes, cancer, autoimmune diseases and spinal cord injury. ROCK2 is a central effector of a fundamental signaling pathway which serves to modify cell shape and cell migration in response to a variety of stimuli.

Commenting on the agreement, Samuel D. Waksal, Ph.D., Chairman and CEO of Kadmon, said: "Our development approach seeks to combine targeted drug candidates, acquired or internally developed, with innovative clinical strategies focused on sub-categories of disease, as determined by genetics, genomics, and other personalizing factors. This transaction brings to Kadmon remarkably well-developed clinical compounds targeting important pathways of disease as well as a powerful discovery engine, both having benefited from substantial investment to date. These assets continue the expansion of our pipeline and align with our strategic vision for advancing novel compounds derived from leading science."

Myer Berlow, CEO of Nano Terra, said: "The ability to make intricate chemical changes which enable or increase the effectiveness of pharmaceutics in addressing diseases is one of the great promises of nanotechnology. This partnership will bring that promise closer to reality."

He added: "Our agreement with Kadmon represents the successful application of Nano Terra's proven co-development model and the expansion of our chemistry and nanotechnology expertise into the life sciences. Kadmon offers tremendous scientific and clinical expertise, unique insights on drug development, as well as a record of significant value creation. We look forward to collaborating with them on this exciting and promising venture."

####

About Nano Terra, Inc.
Nano Terra, Inc. is a privately-held research and development company which has field-exclusive licenses to more than 50 patents on work done by co-founder George Whitesides at the renowned Whitesides Lab at Harvard University, where he is the Woodford L. and Ann A. Flowers University Professor. Whitesides was the winner of the prestigious Benjamin Franklin Medal in Chemistry in 2009.

Key components of Nano Terra’s expertise include Surface Engineering techniques (such as Soft Lithography, Self-Assembly, and Surface Chemistry), and the application of novel Nanomaterials. Nano Terra assembles structures and chemistries at all length scales (from nano- to micro-) on flat, curved, smooth, and uneven surfaces made of a broad range of materials, including metals, polymers, oxides, and ceramics.

ABOUT KADMON PHARMACEUTICALS

Kadmon Pharmaceuticals LLC is a privately held, New York City-based biopharmaceutical company founded on its expertise in novel science. The company explores new understandings in molecular biology to develop therapies that target the metabolomic or signaling pathways associated with disease, including novel anti hepatitis C therapies. Collaborating with academic centers and private enterprise at the forefront of innovation, Kadmon is focused on pioneering medicines in the areas of oncology, infectious diseases and immunology. For more information, visit www.kadmon.com.

For more information, please click here

Contacts:
Grace

(646) 805-2058

Copyright © Nano Terra, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Nanomedicine

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

Announcements

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Patents/IP/Tech Transfer/Licensing

System creates on-demand 'nanotube forests,' has potential industry applications April 20th, 2016

Smaller. Cheaper. Better. Iron nitride transformers developed at Sandia could boost energy storage options March 28th, 2016

Correction: Solar fuels: Protective layer for the 'artificial leaf' March 22nd, 2016

New nanoparticle technology to decipher structure and function of membrane proteins March 9th, 2016

Alliances/Trade associations/Partnerships/Distributorships

Electrically Conductive Graphene Ink Enables Printing of Biosensors April 23rd, 2016

Leti Extends Collaboration with Qualcomm on CoolCubeTM 3D Integration Technology for High-Density, High-Performance ICs: Collaboration Goals Include Building an Ecosystem To Take the Chip-stacking Technology from Design to Fabrication April 13th, 2016

FEI Partners with Five Pharmaceutical Companies, the Medical Research Council and the University of Cambridge to form Cryo-EM Research Consortium April 5th, 2016

Strem Chemicals and SONA Nanotech Sign Distribution Agreement for the World’s First Gold Nanorods Synthesized without CTAB February 24th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic